Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5887900 | Seminars in Arthritis and Rheumatism | 2012 | 11 Pages |
Abstract
The all-cause mortality rate in RA patients treated with anti-TNF biologics was lower than in previous studies in similar non-US populations, but comparable to mortality rates in the US general population. Fatal infection and fatal malignancy rates were similar across anti-TNF biologic groups. Further studies, designed to detect risk differences associated with anti-TNF biologic use and baseline risk factors, would provide additional information.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Veena MPH, Heather MS, Kimberly A. PhD, Pavel MD, MPH, Cheryl PhD,